Highlights

  • BrainChip closed the December quarter with USD 31.7 million in cash following a AUD 35 million capital raise.
  • The AKD1500 neuromorphic edge AI chip entered volume production, with initial customer orders received.
  • The ASX All Technology Index fell 1.84% to 3,183.50, adding pressure to technology stocks during the session.

BrainChip Holdings Ltd (ASX:BRN) touched its 52-week low of AUD 0.16 per share during Thursday’s trading session. The decline in BrainChip shares occurred alongside a wider sell-off in technology stocks. The move coincided with a broader pullback, with the S&P/ASX 200 down 0.07% to 8,927.50, while the S&P/ASX All Technology Index (ASX:XTX) fell 1.84% to 3,183.50.

On 29 January 2026, the company release of BrainChip’s Quarterly Activities Report for the quarter ended December 2025.

Capital Raising Lifts Cash Balance

During the December quarter, BrainChip completed a AUD 35 million fully underwritten institutional placement to professional and sophisticated investors. The company also finalised an oversubscribed Share Purchase Plan, exceeding its original AUD 2 million target.

As a result of the capital raising, BrainChip closed the quarter with a cash balance of USD 31.7 million, up from USD 13.9 million in the prior quarter. Net operating cash outflows improved to USD 3.5 million, compared with USD 4.9 million previously. Payments to suppliers and employees declined to USD 4.3 million, down from USD 5.2 million in the September quarter.

AKD1500 Enters Volume Production

BrainChip commenced volume production of its AKD1500 neuromorphic Edge AI accelerator during the quarter. The chip delivers up to 800 giga operations per second while operating below 300 milliwatts, targeting use cases where low power consumption and on-device processing are required.

The AKD1500 has been integrated into multiple customer solutions across defence, medical, and industrial applications. In December 2025, BrainChip received an initial order for 1,200 AKD1500 chips from Nex Novus for neuromorphic multi-sensor data evaluation.

Defence Partnership and IP Growth

A strategic partnership with Blue Ridge Envisioneering, a Parsons company, includes an initial order of 10,000 chips and a supply framework supporting manufacturing scale and continuity of supply. The collaboration focuses on deploying edge AI systems that operate without cloud connectivity.

During the quarter, BrainChip expanded its global intellectual property portfolio to 61 issued and pending patents across the United States, Europe, and the Asia-Pacific region.